Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride

NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and...

New Diabetes Drug Shows Promise in Trial

... liraglutide mimics effects of a natural hormone, researchers s...hDay News) -- An experimental diabetes drug called liraglutide appears to outperform exenatide (Byetta), the only...ed by liraglutide's maker, Novo Nordisk, shows. liraglutide is a laboratory-made version of glucagon-like pept...

A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market

... Advantages in Efficacy and Safety Will Make liraglutide the New Clinical Gold Standard Drug by 2011, Acco...n over Hypoglycemia also finds that Novo Nordisk's liraglutide will become the new Decision Resources' proprietar... as surveyed primary care physicians indicate that liraglutide has competitive advantages in terms of efficacy an...

Pipeline for New Obesity Therapies is Focus of New Report

...ylin/Alkermes), exenatide + recombinant leptin (r-metHuLeptin; Amylin/Amgen), Symlin (pramlintide; Amylin), pramlintide + AC162352 (PYY 3-36; Amylin), liraglutide (NN2211; Novo Nordisk), albiglutide (GSK / Human Genome Science), PC-DAC:Exendin-4 (ConjuChem), Boc5 (SH-7871; UC Riverside / Chinese Academy of Scien...

Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report

... (Amylin), pramlintide + leptin (Amylin/Amgen), Galvus (vildagliptin; Novartis), alogliptin (Takeda), saxagliptin (BMS/AZ), Redona (denagliptin; GSK), liraglutide (Novo Nordisk), Boc5 (UC Riverside / Chinese Acad. Sci.), substituted quinoxalines (Pfizer/Novo Nordisk), Actos (pioglitazone; Takeda/Lilly), Avandia ...

Liraglutide in Medical Technology

The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide

NEW ORLEANS, June 8 /PRNewswire/ -- Today, The Lancet published online the results of the Novo Nordisk (NVO) LEAD(TM) 6 study, a direct comparison between two products in a new class of diabetes treatments, the GLP-1 receptor agonists. Results show that patients treated with liraglutide had a...

Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162

NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented today at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sug...

Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes

SILVER SPRING, Md., April 2 /PRNewswire-FirstCall/ -- Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) has finalized its discussions of questions related to liraglutide, a once-daily human GLP-1 anal...

Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet

PRINCETON, N.J., Sept. 25 /PRNewswire/ -- Data from a 52-week phase 3 study (LEADTM 3) of Novo Nordisk's (NYSE: NVO ) liraglutide, a once-daily human GLP-1 analog, were published online today in The Lancet. The study showed that liraglutide, when taken alone, produces statistically significan...

Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes

ROME, Sept. 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO ), a global healthcare company, presented data from a phase 3 clinical study (LEAD(TM) 4) today at the 44th annual meeting of the European Association for the Study of Diabetes that demonstrated adding the investigational new dru...

Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes

Phase 3 data highlight sustained efficacy and benefits of early treatment with liraglutide versus glimepiride SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Data presented today at the 68th Scientific Sessions of the American Diabetes Association (ADA) demonstrated that once-d...

Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study

...esults from the first of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The 26-week...end of the study, more than 50% of patients in the liraglutide group had reached the American Diabetes Associatio...e study, the difference in body weight between the liraglutide and insulin glargine treatment groups was on avera...

Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target

...ted over a period of 14 weeks. Results showed that liraglutide was effective and well tolerated within a wide dos... considerable advance in diabetes treatment." liraglutide acts to lower blood glucose when levels are elevat...domized to receive one of four once-daily doses of liraglutide (0.1, 0.3, 0.6, and 0.9 mg) or placebo. Baseline A...

Liraglutide in Biological Technology

New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes

MONTREAL, Oct. 17 /PRNewswire-FirstCall/ -- Today, at the Canadian Diabetes Association Congress, physicians will get a first-time look at more detailed results from a phase 3b clinical study (LEAD(TM) 6) comparing the investigational new drug liraglutide to exenatide. The study showed that li...

Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide

...ice president and chief science officer for Novo Nordisk A/S. "The broadening of Novo Nordisk's diabetes therapeutic portfolio with the development of liraglutide and other novel molecules in the pipeline, and the increasing importance of the U. S. to the Novo Nordisk business, requires a leader with clinical an...